瑞士肺癌发病率和死亡率趋势：可能的解释和未解决的问题。
Trends in incidence and mortality of lung cancer in Switzerland: Possible explanations and open questions.
机构信息
Department of Oncology, Geneva University Hospital, SCCL, Switzerland.
Department of Oncology, Geneva University Hospital, SCCL, Switzerland; Clinique Générale Beaulieu, Geneva, Switzerland.
出版信息
Cancer Epidemiol. 2022 Oct;80:102232. doi: 10.1016/j.canep.2022.102232. Epub 2022 Jul 26.
BACKGROUND
Using US population-level data, it has been suggested that novel treatment advances, particularly targeted therapies, have contributed to a sharp fall in NSCLC mortality. Switzerland is a high-income country, with a universal, highly performant health care system, easy access to novel drugs but with different dynamics concerning the smoking epidemic than the US.
METHODS
We use population-based data from Swiss cancer registries to analyze the trends in incidence, mortality and survival and relate them to recent drug approvals.
RESULTS
The incidence of NSCLC and SCLC was stable from 1980 to 2018. We noted an important difference between sexes, with an important decrease in men and increase in women, especially for NSCLC. 1-y and 5-y survival have improved for NSCLC between 2004 and 2008 and 2014-2018.
CONCLUSION
These findings should be regarded as the results of a multifactorial improvement in care and it is difficult for us to pinpoint a unique cause explaining the reduction in mortality.
背景
利用美国人群水平数据，有研究表明，新型治疗方法的进步，特别是靶向治疗，对非小细胞肺癌死亡率的急剧下降起到了作用。瑞士是一个高收入国家，拥有普及且高效的医疗保健系统，新药的可及性高，但与美国相比，其吸烟流行的动态有所不同。
方法
我们利用瑞士癌症登记处的基于人群的数据，分析发病率、死亡率和生存率的趋势，并将其与最近的药物批准情况相关联。
结果
1980 年至 2018 年期间，非小细胞肺癌和小细胞肺癌的发病率保持稳定。我们注意到性别之间存在重要差异，男性发病率下降，女性发病率上升，尤其是非小细胞肺癌。2004 年至 2008 年和 2014 年至 2018 年期间，非小细胞肺癌的 1 年和 5 年生存率有所提高。
结论
这些发现应被视为护理多方面改善的结果，我们很难确定一个独特的原因来解释死亡率的降低。
Zotero 插件